Mental health · Arkansas
Mental health studies in Arkansas
50 studies have at least one recruiting site in Arkansas. Mental health research includes studies of depression, anxiety, PTSD, bipolar disorder, schizophrenia and ADHD, testing medicines, devices and talk therapies.
50 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Little Rock, AR + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Bryant, AR + 44 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Vanda Pharmaceuticals
- Location
- Little Rock, AR + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Reunion Neuroscience Inc
- Location
- Little Rock, AR + 26 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 2
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
TG Therapeutics, Inc.
- Location
- Little Rock, AR + 1 other US site
- Eligibility basics
- Ages 18–60
- RecruitingPhase 4
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Neurocrine Biosciences
- Location
- Bryant, AR + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
Transcend Therapeutics
- Location
- Little Rock, AR + 36 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
AbbVie
- Location
- Little Rock, AR + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bristol-Myers Squibb
- Location
- Bentonville, AR + 39 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
52-week Open Label Safety-Tolerability Study
LB Pharmaceuticals Inc.
- Location
- Bentonville, AR + 22 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc.
- Location
- Little Rock, AR + 14 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
AbbVie
- Location
- Bryant, AR + 32 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Bryant, AR + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
Novartis Pharmaceuticals
- Location
- Bentonville, AR + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
LB Pharmaceuticals Inc.
- Location
- Bentonville, AR + 12 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
LB Pharmaceuticals Inc.
- Location
- Bentonville, AR + 25 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Bryant, AR + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Bristol-Myers Squibb
- Location
- Bentonville, AR + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
AbbVie
- Location
- Little Rock, AR + 32 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
atai Therapeutics, Inc.
- Location
- Little Rock, AR + 33 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Bryant, AR + 20 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Randomized Withdrawal Study in Patients With Schizophrenia
Vanda Pharmaceuticals
- Location
- Rogers, AR + 21 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Little Rock, AR + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study of ALTO-300 in MDD
Alto Neuroscience
- Location
- Rogers, AR + 36 other US sites
- Eligibility basics
- Ages 18–70
Who these studies look for
Studies usually require a confirmed diagnosis and stable circumstances, and they monitor safety closely. If you are in crisis, contact a crisis line or emergency services rather than a study.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Will joining affect my current treatment?
Some studies require changes to medicines, which the study team manages; others add to your usual care. Talk to your own clinician before making any change.